ABSTRACT
Objective@#To evaluate the application effect of the medication management training based on Precede-Proceed Model in schizophrenic inpatients.@*Methods@#In this self-control study, 60 schizophrenic inpatients were chosen for this investigation and were undergoing the medication management training on Precede-Proceed Model with conventional nursing care. By using Insight and Treatment Attitudes Questionnaires (ITAQ), The Brief Psychiatric Rating Scale (BPRS) and Nurses′ Observation Scale for Inpatient Evaluation (NOSIE) after the first 3 months and 6 months of the intervention, in order to evaluate their results with their initial readings.@*Results@#The total scores of ITAQ, the total scores of BPRS, lacking in activity factor, reaction factor, hostile-suspiciousness factor, the total scores of NOSIE, total positive and negative factors before the intervention were (183.3±15.0) points, (71.7±10.9) points and (13.6±8.8) points; three months after intervention were (189.0±15.8) points, (75.3±11.1) points and (11.6±7.2) points; six months after intervention were (193.8 months after intervention were15.2) points, (71.8 ±9.6) points and (10.1±7.0) points. There were significant differences between the total score and the total negative factor score before and after treatment (F=43.244, 23.060, P<0.05).@*Conclusion@#The Precede-Proceed Model on medication management training in schizophrenic inpatients plays a positive role in promoting recovery and it is worth extending in clinical practice.
ABSTRACT
Objective To evaluate the application effect of the medication management training based on Precede-Proceed Model in schizophrenic inpatients. Methods In this self-control study, 60 schizophrenic inpatients were chosen for this investigation and were undergoing the medication management training on Precede-Proceed Model with conventional nursing care. By using Insight and Treatment Attitudes Questionnaires (ITAQ), The Brief Psychiatric Rating Scale (BPRS) and Nurses′Observation Scale for Inpatient Evaluation (NOSIE) after the first 3 months and 6 months of the intervention, in order to evaluate their results with their initial readings. Results The total scores of ITAQ, the total scores of BPRS, lacking in activity factor, reaction factor, hostile-suspiciousness factor, the total scores of NOSIE, total positive and negative factors before the intervention were (183.3±15.0) points, (71.7±10.9) points and (13.6±8.8) points; three months after intervention were (189.0±15.8) points, (75.3± 11.1) points and (11.6 ± 7.2) points; six months after intervention were (193.8 months after intervention were15.2) points, (71.8 ±9.6) points and (10.1±7.0) points. There were significant differences between the total score and the total negative factor score before and after treatment (F=43.244, 23.060, P﹤0.05). Conclusion The Precede-Proceed Model on medication management training in schizophrenic inpatients plays a positive role in promoting recovery and it is worth extending in clinical practice.
ABSTRACT
Objective To observe the influence of α-lipoic acid on nerve conduction velocity in the treatment of type 2 diabetes with peripheral neuropathy,to provide a theoretical basis for clinical treatment.Methods 90 type 2 diabetes patients with peripheral neuropathy were included in this study.The patients were randomly divided into the observation group and the control group,45 cases in each group.The control group was given conventional therapy,containing hypoglycemic comprehensive intervention and neurotrophic treatment.The observation group was given αt-lipoic acid treatment,600mg/d,21d for a course of treatment.The motor and sensory nerve conduction velocity were measured by EMG after a course,and the peripheral neuropathy symptoms (limb pain,numbness,fever,cold,hypoesthesia) before and after treatment were observed,the clinical efficacy was evaluated.Results The motor nerve conduction velocity (median nerve,tibial nerve,peroneal nerve) and sensory nerve conduction velocity (median nerve,peroneal nerve) of the observation group after treatment were significantly higher than before treatment (t =3.946,4.175,3.887,3.915,4.034,all P ＜ 0.05),but the median nerve sensory conduction velocity of the control group had no significant difference before and after treatment(P ＞ 0.05).The motor nerve conduction velocity (median nerve,tibial nerve,peroneal nerve) and sensory nerve conduction velocity (median nerve,peroneal nerve) of the observation group after treatment were significantly higher than the control group (t =3.488,3.585,3.362,3.246,3.505,all P ＜ 0.05).The efficacy of limb pain,numbness,fever,cold,feeling diminished of the observation group were 71.43％,78.95％,62.5％,61.54％,59.26％,which were significantly higher than 36.36％,43.24％,21.4％,29.17％,28％ of the control group(all P ＜0.05).The total effective rate of the observation group was 84.44％,which was significantly higher than 64.44％ of the control group (x2 =6.925,P ＜ 0.05).Conclusion α-lipoic acid can improve the motor nerve conduction velocity and sensory nerve conduction velocity of type 2 diabetes patients with peripheral neuropathy,significantly relieve the positive symptoms of DPN and improve clinical efticacy,which is worthy of clinical use.
ABSTRACT
Objective To investigate the effect of C-erbB-2 shRNA on chemosensitivity of mouse lung adenocarcinoma cells and its mechanism,and to find new therapy method for non-small cell lung cancer,especial lung adenocarcinoma.Methods The mouse lung adenocarcinoma Lewis cells were cultured regularly and divided into non-transfected group, pGPU6/RFP/Neo-shNC group and pGPU6/RFP/Neo-erbB-2 group. The plasmids were synthesized and transfected into Lewis cells in each group by Lipofectamine 2000.The expression levels of C-erbB-2 mRNA and protein in the cells in various groups were tested by RT-PCR and Western blotting method, respectively. The Lewis cells were divided into non- transfected group, pGPU6/RFP/Neo-shNC group, carboplatin group, pGPU6/RFP/Neo-erbB-2 group, pGPU6/RFP/Neo-shNC+carboplatin group and pGPU6/RFP/Neo-erbB-2+ carboplatin group. The apoptotic rates of the cells in each group were detected by flow cytometry;the expression levels of Bcl-2 and Bax proteins in each group were determined by Western blotting method.Results The expression levels of C-erbB-2 mRNA and protein in pGPU6/RFP/Neo-erbB-2 group were lower than those in non-transfected group and pGPU6/RFP/Neo-shNC.The apoptotic rate of the cells in pGPU6/RFP/Neo-erbB-2+carboplatin group was the highest in all of the groups (P<0.01);compared with the others, the expression of Bax protein in pGPU6/RFP/Neo-erbB-2+carboplatin group was increased, while the expression level of Bcl-2 protein was decreased.Conclusion C-erbB-2 shRNA can increase the Lewis cells’sensitivity to carboplatin.The mechanism may be that it can enhance the Lewis cells’apoptosis induced by carboplatin through increasing the expression of Bax protein and decreasing the expression of Bcl-2 protein.